Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans

Obesity Surgery

Volumn 24, Issue 2, 2014, Pages 241-252

  Yousseif, Ahmed ^a,b   Emmanuel, Julian ^a   Karra, Efthimia ^a   Millet, Queensta ^a   Elkalaawy, Mohamed ^b,c   Jenkinson, Andrew D ^b   Hashemi, Majid ^b   Adamo, Marco ^b   Finer, Nicholas ^b   Fiennes, Alberic G ^d   Withers, Dominic J ^e   Batterham, Rachel L ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d St Anthony's Hospital   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Active glucagon like petide 1 (GLP 1); Acyl ghrelin; Appetite; Laparoscopic Roux en Y gastric bypass (LRYGBP); Laparoscopic sleeve gastrectomy (LSG); Peptide YY3 36 (PYY3 36)

Indexed keywords

ACYL GHRELIN; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; LEPTIN; PEPTIDE YY [3-36]; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRY; APPETITE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENTEROENDOCRINE CELL; EXPOSURE; FEMALE; HORMONE DETERMINATION; HUMAN; HUNGER; LAPAROSCOPIC GASTRIC BYPASS; LAPAROSCOPIC SLEEVE GASTRECTOMY; MIDDLE AGED; NUTRIENT; OBESITY; PHENOTYPE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ROUX Y ANASTOMOSIS; SATIETY; SLEEVE GASTRECTOMY; WEIGHT REDUCTION;

ADOLESCENT; ADULT; APPETITE; BODY MASS INDEX; FEMALE; GASTRECTOMY; GASTRIC BYPASS; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LAPAROSCOPY; MIDDLE AGED; OBESITY, MORBID; PEPTIDE FRAGMENTS; PEPTIDE YY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84893694422     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-1066-0     Document Type: Article

References (47)

1. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56-65.
2. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301:R15-27.
3. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735-40.
4. Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab. 2009;35:513-7.
5. Olivan B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg. 2009;249:948-53.
6. Gould JC, Kent KC, Wan Y, et al. Perioperative safety and volume: outcomes relationships in bariatric surgery: a study of 32,000 patients. J Am Coll Surg. 2011;213:771-7.
7. Deitel M, Gagner M, Erickson AL, et al. Third international summit: current status of sleeve gastrectomy. Surg Obes Relat Dis. 2011;7:749-59.
8. Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141:950-8.
9. Paluszkiewicz R, Kalinowski P, Wroblewski T, et al. Prospective randomized clinical trial of laparoscopic sleeve gastrectomy versus open Roux-en-Y gastric bypass for the management of patients with morbid obesity. Wideochir Inne Tech Malo Inwazyjne. 2012;7:225-32.
10. Vidal P, Ramon JM, Goday A, et al. Laparoscopic gastric bypass versus laparoscopic sleeve gastrectomy as a definitive surgical procedure for morbid obesity. Mid-term results, Obes Surg. 2013;23:292-9.
11. Hillman JB, Tong J, Tschop M. Ghrelin biology and its role in weight-related disorders. Discov Med. 2011;11:521-8.
12. Hosoda H, Doi K, Nagaya N, et al. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem. 2004;50:1077-80.
13. Chandarana K, Drew ME, Emmanuel J, et al. Subject standardization, acclimatization, and sample processing affect gut hormone levels and appetite in humans. Gastroenterology. 2009;136:2115-26.
14. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 2006;4:223-33.
15. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 2003;994:162-8.
16. Nadkarni PP, Costanzo RM, Sakagami M. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Diabetes Obes Metab. 2011;13:408-17.
17. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology. 2005;146:879-88.
18. Sloth B, Holst JJ, Flint A, et al. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab. 2007;292:E1062-8.
19. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-604.
20. Valderas JP, Irribarra V, Rubio L, et al. Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. Obes Surg. 2011;21:902-9.
21. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234-41.
22. Morinigo R, Vidal J, Lacy AM, et al. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg. 2008;247:270-5.
23. Chronaiou A, Tsoli M, Kehagias I, et al. Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg. 2012;22:1761-70.
24. R. Barazzoni, A. Semolic, M.R. Cattin, M. Zanetti, G. Guarnieri. Acylated ghrelin limits fat accumulation and improves redox state and inflammation markers in the liver of high-fat-fed rats. Obesity (Silver Spring). 2013.
25. Melissas J, Daskalakis M, Koukouraki S, et al. Sleeve gastrectomy-a "food limiting" operation. Obes Surg. 2008;18:1251-6.
26. Baumann T, Kuesters S, Grueneberger J, et al. Time-resolved MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy-preliminary results. Obes Surg. 2011;21:95-101.
27. J. Melissas, A. Leventi, I. Klinaki, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Annals of Surgery. 2012.
28. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247:401-7.
29. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and Hormonal Changes After Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: a Randomized. Obes Surg: Prospective Trial; 2012.
30. Ramon JM, Salvans S, Crous X, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16:1116-22.
31. F. Romero, J. Nicolau, L. Flores, R. Casamitjana, A. Ibarzabal, A. Lacy, J. Vidal, Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects, Surg Endosc, (2012)
32. Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069-75.
33. Alam ML, Van der Schueren BJ, Ahren B, et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:378-81.
34. Kirchner H, Gutierrez JA, Solenberg PJ, et al. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med. 2009;15:741-5.
35. Gonzalez CR, Vazquez MJ, Lopez M, et al. Influence of chronic undernutrition and leptin on GOAT mRNA levels in rat stomach mucosa. J Mol Endocrinol. 2008;41:415-21.
36. Goebel-Stengel M, Hofmann T, Elbelt U, et al. The ghrelin activating enzyme ghrelin-O-acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass index. Peptides. 2013;43:13-9.
37. Gagner M, Deitel M, Kalberer TL, et al. The second international consensus summit for sleeve gastrectomy. Surg Obes Relat Dis. 2009;5:476-85.
38. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
39. Sundbom M, Holdstock C, Engstrom BE, et al. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg. 2007;17:304-10.
40. Bohdjalian A, Langer FB, Shakeri-Leidenmuhler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20:535-40.
41. Falken Y, Hellstrom PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227-35.
42. Rigamonti AE, Agosti F, Compri E, et al. Anorexigenic postprandial responses of PYY and GLP1 to slow ice cream consumption: preservation in obese adolescents, but not in obese adults. Eur J Endocrinol. 2013;168:429-36.
43. Kim BJ, Carlson OD, Jang HJ, et al. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab. 2005;90:6665-71.
44. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009;124:44-56.
45. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.
46. Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2004;151:573-7.
47. Campos GM, Rabl C, Mulligan K, et al. Factors associated with weight loss after gastric bypass. Arch Surg. 2008;143:877-83. discussion 884.